Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00930059
Other study ID # B0401005
Secondary ID 2009-012179-82
Status Completed
Phase Phase 2
First received
Last updated
Start date September 10, 2009
Est. completion date September 22, 2010

Study information

Verified date October 2020
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects of PF-04447943 compared to placebo on cognitive, behavioral and overall symptoms of Alzheimer's disease; evaluate the safety and tolerability of PF-0444793 compared to placebo; and determine the levels of PF-04447943 in the plasma over the course of the study.


Recruitment information / eligibility

Status Completed
Enrollment 191
Est. completion date September 22, 2010
Est. primary completion date September 22, 2010
Accepts healthy volunteers No
Gender All
Age group 55 Years to 85 Years
Eligibility Inclusion Criteria: - Mild to moderate Alzheimer's disease (MMSE 14-26) - Good general health (such controlled conditions as Type 2 diabetes and hypertension allowed) Exclusion Criteria: - Use of acetylcholinesterase inhibitors (donepezil, rivastigmine, or galantamine) or memantine within 12 weeks of the start of the study - Significant cardiovascular disease in the past 6 months - Illness other than Alzheimer's disease that could contribute to cognitive impairment - History of stroke or seizure disorder

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PF-04447943
tablets, 25 mg every 12 hours for 12 wks
Placebo
matching placebo tablets, every 12 hours for 12 wks

Locations

Country Name City State
Canada Neuro Rive Sud Clinic Greenfield Park Quebec
Canada Hamilton Health Sciences Hamilton Ontario
Canada Medical Arts Health Research Group Kelowna British Columbia
Canada Kawartha Regional Memory Clinic Peterborough Ontario
Canada Diex Recherche Inc. Sherbrooke Quebec
Chile Psicomed Estudios Clinicos Antofagasta II Region
Chile Neuropsicologia Ltda. La Florida Santiago
Chile Centro Doctora Lissette Duque Providencia RM
Chile Especialidades Medicas L y S Santiago RM
Chile Hospital Del Salvador Santiago RM
Chile Neuroconsult Santiago RM
Chile Psicomedica Research Group Santiago RM
Chile Hospital Base Valdivia Valdivia XIV Region
Czechia Fakultni nemocnice Hradec Kralove
Czechia Pardubicka krajska nemocnice, a.s. Pardubice
Czechia Pragtis, s.r.o. Praha 2
Czechia Fakultni nemocnice v Motole Praha 5
Czechia Psychiatry Trial, s.r.o. Praha 5
Czechia Neurologie - EEG, s.r.o Praha 8
Czechia Psychiatricka ambulance Praha 8
Czechia Centrum neurologicke pece, s.r.o. Rychnov nad Kneznou
Czechia Psychiatricka ambulance Strakonice
United States Neurobehavioral Research Inc Cedarhurst New York
United States Neurology Clinic, PC Cordova Tennessee
United States ATP Clinical Research, Inc. Costa Mesa California
United States Fort Wayne Neurological Center Fort Wayne Indiana
United States Southwestern Research Incorporated Glendale California
United States MD Clinical Hallandale Beach Florida
United States Agewell Indianapolis Indiana
United States Joliet Center for Clinical Research Joliet Illinois
United States Advanced MRI Lake Charles Louisiana
United States Lake Charles Clinical Trials, LLC Lake Charles Louisiana
United States Pacific Coast Imaging (for Imaging only) Newport Beach California
United States Neurocare, Inc. Newton Massachusetts
United States Neurology Clinic, PC Northport Alabama
United States Compass Research, LLC Orlando Florida
United States Four Rivers Clinical Research, Inc. Paducah Kentucky
United States University of Pittsburgh Alzheimer's Disease Research Center Pittsburgh Pennsylvania
United States Berma Research Group Plantation Florida
United States Rhode Island Hospital, Alzheimer's Disease and Memory Disorders Center Providence Rhode Island
United States The Southwest Institute for Clinical Research, Inc. Rancho Mirage California
United States Pacific Research Network (Satellite Site) San Diego California
United States Behavioral Medical Research of Staten Island Staten Island New York
United States Pacific Research Network, Inc. (Satellite Site) Vista California

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

United States,  Canada,  Chile,  Czechia, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of Participants With Laboratory Test Abnormalities Criteria for laboratory test abnormality: a) Hematology: white blood cells (WBC) <0.6*lower limit of normal (LLN)/>1.5*upper limit of normal (ULN), hemoglobin, hematocrit, red blood cells (RBC), lymphocytes <0.8*LLN, total neutrophils <0.8*LLN/ >1.2*ULN, basophils, eosinophils, monocytes >1.2*ULN; b) Liver Function: total bilirubin >1.5*ULN, aspartate aminotransferase (AT), alanine AT[>0.3*ULN, total protein, albumin <0.8*LLN/ >1.2*ULN; c) Renal Function: creatinine >1.3*ULN, uric acid >1.2*ULN; d) Electrolytes: sodium <0.95*LLN/ >1.05*ULN, potassium, chloride, bicarbonate <0.9*LLN/ >1.1*ULN; e) Clinical Chemistry: glucose <0.6*LLN/ >1.5*ULN, glycosylated hemoglobin >1.3*ULN; f) Urinalysis: ketones, protein, blood/hemoglobin, urine glucose >=1, RBC, WBC >=6, hyaline casts >1; g) Hormones: tetraiodothyronine (T4), triiodothyronine (T3) and thyroid stimulating hormone (TSH) <0.8*LLN/1.2*ULN. Baseline up to Week 12
Other Number of Participants With Pre-defined Criteria for Electrocardiogram (ECG) Abnormalities Criteria for ECG (12-lead) abnormalities were as follow: 1) PR interval: greater than and equal to (>=) 300 milliseconds (msec), 2) PR interval: maximum increase from baseline >=25 percent (%) (if baseline PR interval greater than [>] 100 msec) or >=50% (if baseline PR interval less than or equal to [<=] 100 msec); 3) QRS complex: >=200 msec, 4) QRS complex: maximum increase from baseline >=25% or >=50%; 5) QT interval >=500 msec; 6) QT interval corrected using Bazett's formula (QTcB): 450 to less than (<) 480 msec, 7) QTcB: 480 to <500 msec, 8) QTcB: >=500 msec, 10) QTcB: 30 to <60 msec increase from baseline, 11) QTcB: >=60 msec increase from baseline; 9) QT interval corrected using the Fridericia's formula (QTcF): 450 to <480 msec, 10) QTcF: 480 to < 500 msec, 11) QTcF: >=500 msec, 12) QTcF: 30 to <60 msec increase from baseline, 13) QTcF: change>=60 msec increase from baseline. Baseline up to Week 12
Other Number of Participants With Abnormal Physical Examinations and Neurological Examinations The complete physical and neurological examination included examination of abdomen, ears, extremities, eyes, general, head, heart, lungs, lymph nodes, mouth, musculoskeletal, neck, nose, ocular fundi, pulse, skin, throat, thyroid, and others. Abnormality was judged by investigator. Screening (28 days before Baseline), Week 12
Other Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) C-SSRS assessed whether participant experienced the following: suicidal behavior which includes suicide attempt, interrupted attempt, aborted attempt, and preparatory acts towards imminent suicidal behavior (response of "Yes" on "preparatory acts or behavior"); suicidal ideation (response of "Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent); self-injurious behavior (SIB), intent unknown (response of "Yes" on "Has subject engaged in Non-suicidal Self-Injurious Behavior?"). Screening, Baseline, Post-baseline (Week 1 up to 12)
Other PF-04447943 Plasma Concentration Pre-dose on Week 1; 0 to 3 hours following cognitive testing at Week 3, 6, 9, 12
Other Number of Participants With Pre-defined Criteria of Vital Signs Abnormalities Pre-defined criteria vital signs abnormalities included maximum increase or decrease of greater than or equal to (>=) 30 millimeters of mercury (mmHg) from baseline for supine systolic blood pressure (SBP); maximum increase or decrease of >=20 mmHg from baseline for supine diastolic BP (DBP); maximum increase or decrease of >=30 mmHg from baseline for standing SBP; maximum increase or decrease of >=20 mmHg from baseline for standing DBP. Orthostatic hypotension was defined as a drop of more than 10 mmHg in diastolic BP or a drop of more than 20 mmHg in systolic BP within 3 minutes of standing from the supine position. Baseline up to Week 12 for change in supine or standing blood pressure; Week 1, 3, 6, 9, 12 for orthostatic hypotension
Primary Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) Score at Baseline ADAS-cog is a structured scale assessing the severity of cognitive impairment in Alzheimer's disease. It comprises of following 11 items (range): word recall (0-10), naming objects and fingers (0-5), following commands (0-5), constructional praxis (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), recall of test instructions (0-5), spoken language ability (0-5), word-finding difficulty (0-5), comprehension of spoken language (0-5). Total ADAS-cog 70 score was sum of all items and ranged from 0 (least impairment) to 70 (most severe impairment), higher score indicating worse cognition. Baseline (Day 1)
Primary Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 12 ADAS-cog is a structured scale assessing the severity of cognitive impairment in Alzheimer's disease. It comprises of following 11 items (range): word recall (0-10), naming objects and fingers (0-5), following commands (0-5), constructional praxis (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), recall of test instructions (0-5), spoken language ability (0-5), word-finding difficulty (0-5), comprehension of spoken language (0-5). Total ADAS-cog 70 score was sum of all items and ranged from 0 (least impairment) to 70 (most severe impairment), higher score indicating worse cognition. Baseline, Week 12
Secondary Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale 70 (ADAS-Cog 70) at Week 3, 6 and 9 ADAS-cog is a structured scale assessing the severity of cognitive impairment in Alzheimer's disease. It comprises of following 11 items (range): word recall (0-10), naming objects and fingers (0-5), following commands (0-5), constructional praxis (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), recall of test instructions (0-5), spoken language ability (0-5), word-finding difficulty (0-5), comprehension of spoken language (0-5). Total ADAS-cog 70 score was sum of all items and ranged from 0 (least impairment) to 70 (most severe impairment), higher score indicating worse cognition. Baseline, Week 3, 6, 9
Secondary Clinical Global Impression - Improvement (CGI-I) CGI-I is a 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Week 3, 6, 9, 12
Secondary Neuropsychiatric Inventory (NPI) Total Score at Baseline NPI total score evaluates disturbances in 12 behavioral domains: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating and night time behavior. NPI total score ranged from 0 (minimum severity) to 144 (maximum severity); higher score indicates greater behavioral disturbances. Baseline
Secondary Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 3, 6, 9 and 12 NPI total score evaluates disturbances in 12 behavioral domains: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, appetite/eating and night time behavior. NPI total score ranged from 0 (minimum severity) to 144 (maximum severity); higher score indicates greater behavioral disturbances. Baseline, Week 3, 6, 9, 12
See also
  Status Clinical Trial Phase
Completed NCT05040048 - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn NCT03316898 - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease Phase 1
Withdrawn NCT02860065 - CPC-201 Alzheimer's Disease Type Dementia: PET Study Phase 2
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Recruiting NCT05607615 - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease Phase 2
Terminated NCT03307993 - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease Phase 1
Recruiting NCT02912936 - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease N/A
Active, not recruiting NCT02899091 - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease Phase 1/Phase 2
Not yet recruiting NCT02868905 - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women N/A
Completed NCT02907567 - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Completed NCT02580305 - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study Phase 2
Completed NCT02516046 - 18F-AV-1451 Autopsy Study Phase 3
Terminated NCT02521558 - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease N/A
Recruiting NCT02247180 - Cognitive Rehabilitation in Alzheimer`s Disease N/A
Terminated NCT02220738 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors Phase 1
Completed NCT02256306 - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study N/A
Completed NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Completed NCT02260167 - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol N/A
Completed NCT01826110 - PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers Phase 1